| Document |
Document Title |
|
WO/2020/221217A1 |
A fluorescent dye, a preparation method therefor, and a use thereof; the fluorescent dye is sensitive and specific to viscosity response, has the advantage of low background fluorescence, and can be used as a fluorescence activated dot l...
|
|
WO/2020/221038A1 |
A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and...
|
|
WO/2020/218680A1 |
The present invention relates to a novel organic light emitting compound and an organic electroluminescent diode using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light emitt...
|
|
WO/2020/216919A1 |
The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and u...
|
|
WO/2020/218187A1 |
An organic electroluminescent element which comprises a light emitting layer between a positive electrode and a negative electrode facing each other, and which is characterized in that: the light emitting layer contains a first host, a s...
|
|
WO/2020/211836A1 |
Disclosed are a benzene piperidine derivative, a preparation method therefor, an intermediate thereof and a use thereof. Specifically, the present application relates to a compound represented by formula (I) and a preparation method ther...
|
|
WO/2020/212697A1 |
The present invention relates to compounds of Formula (I) that function as inhibitors of serum and glucocorticoid regulated kinase (SGK) activity: Formula (I) wherein X1, X2, Y1, Y2, Y3, Y4, R2, R3, Y and Z are each as defined herein. Th...
|
|
WO/2020/210308A1 |
The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
|
|
WO/2020/210657A1 |
The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
|
|
WO/2020/203610A1 |
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of bloc...
|
|
WO/2020/199996A1 |
Disclosed are a substituted 1,3,5-triazine compound, composition and application thereof. The present invention provides a 1,3,5-triazine compound represented by formula I. The 1,3,5-triazine compound in the present invention can be used...
|
|
WO/2020/205934A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2020/203609A1 |
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type c...
|
|
WO/2020/204112A1 |
[Problem] To provide a novel agricultural chemical, in particular, an herbicide. [Solution] The pyridazinone compound represented by formula (1), and an herbicide containing the compound. (In the formula, W1 and X each independently repr...
|
|
WO/2020/192302A1 |
Disclosed are a pyrimidine-containing tri-substituted imidazole compound having the structure shown in formula (I) and an application thereof. The compound can effectively inhibit EGFR C797S mutations including EGFR ex19del/T790M/C797S a...
|
|
WO/2020/198478A1 |
The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in ani...
|
|
WO/2020/197170A1 |
The present invention provides a novel organic light-emitting material which can be used as a material for an organic material layer of an organic light-emitting device and can improve efficiency, low driving voltage, and/or life charact...
|
|
WO/2020/196327A1 |
A method for industrially advantageously synthesizing a production intermediate of a quinolinecarboxamide derivative or a salt thereof is provided. This method for producing a quinolinecarboxamide derivative represented in formula (4) ...
|
|
WO/2020/188437A1 |
The present invention relates to compounds with a 5-(2-nitroethyI)-2,4,6- triaminopyrimidine structure, derivatised at the 1 position on the ethylene chain with heteroaromatic or phenyl-benzylether rings. The invention also relates to th...
|
|
WO/2020/188049A1 |
The present invention relates to compounds of the general formula (I): (I), wherein V, W, M, R, R and Y have the designations cited below, or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof, and to processes ...
|
|
WO/2020/182929A1 |
The present invention relates to compounds of formula (I): Formula (I) wherein the variables are defined as in claim 1, to compositions comprising at least one of said compounds and at least one agriculturally suitable auxiliary, to the ...
|
|
WO/2020/182070A1 |
Disclosed by the present invention are a compound using triarylamine that contains pyrene or azapyrene as a core and an application thereof. The structure of the organic compound provided by the present invention is as shown in general f...
|
|
WO/2020/184906A1 |
The present invention relates to a novel organic light emitting compound and an organic electroluminescent device using same and, more particularly, to a compound having excellent thermal stability, electrochemical stability, light-emitt...
|
|
WO/2020/185038A1 |
The present invention provides: a novel compound represented by chemical formula 1, which is contained in an organic layer of an organic light emitting device and can bring improved efficiency, low driving voltage, and/or improved servic...
|
|
WO/2020/185026A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2020/177752A1 |
The present invention relates to the technical field of medicine, and specifically disclosed thereby are a 1,2,4-triazole compound represented by formula (I) and a physiologically acceptable salt thereof, a preparation method for the com...
|
|
WO/2020/177587A1 |
The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method compirses administering, to an i...
|
|
WO/2020/176643A1 |
The present disclosure provides heteroaryl compounds and pharmaceutically acceptable salts thereof useful as adjuvants and their use in pharmaceutical compositions such as vaccines. Further disclosed is the use of heteroaryl compounds an...
|
|
WO/2020/174058A1 |
The invention relates to a method for producing quinoxalines by condensation of optionally substituted o-phenylenediamine with a diketone in accordance with the following reaction mechanism (mechanism 4) wherein: R1, R2 and R3 each indep...
|
|
WO/2020/175961A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2020/171531A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2020/171532A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting element comprising same.
|
|
WO/2020/170022A1 |
This invention relates to the novel potentially therapeutic compounds that contain l-acyl derivatives of aziridine-2-carboxamide and their analogues with the anticancer and/or antiproliferative, and/or antimetastatic properties and/or th...
|
|
WO/2020/171530A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/169509A1 |
The invention relates to 4-(4-trifluormethyl-6-cycloropylpyrazolyl)pyrimidines of general formula (I) and to their agrochemically acceptable salts, and to the use thereof in the field of plant protection.
|
|
WO/2020/170202A1 |
A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, Formula A; wherein: ring 1 is an aromatic ring with ...
|
|
WO/2020/169526A1 |
A compound of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2020/168149A1 |
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, ...
|
|
WO/2020/166875A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2020/166874A1 |
The present invention provides a novel compound and an organic light-emitting diode using same.
|
|
WO/2020/166873A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2020/162471A1 |
Provided is a novel compound capable of inhibiting a bond between a BET protein and acetylated lysine. The present invention relates to, for example, the compound represented by general formula (1) or a salt thereof, and a pharmaceutic...
|
|
WO/2020/162703A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting device using same.
|
|
WO/2020/163554A1 |
Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for examp...
|
|
WO/2020/162612A1 |
The present invention provides a compound represented by formula (I'), which has an inhibitory effect on an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt of the compound. (In formula (I'), ring D represents one of t...
|
|
WO/2020/159279A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting element comprising same.
|
|
WO/2020/159333A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2020/156363A1 |
The present application discloses an immunomodulator, and specifically discloses a compound depicted by formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present applicati...
|
|
WO/2020/159340A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2020/157644A1 |
The present invention provides process for the preparation of amorphous canagliflozin substantially free of hydroperoxide impurity. The present invention also provides pharmaceutical compositions comprising amorphous canagliflozin having...
|
